Why the study?
What are the NCCN and ASCO guideline recommendations for the prevention, diagnosis, and treatment of cancer-associated venous thromboembolism?
What are the NCCN and ASCO guideline recommendations for the prevention, diagnosis, and treatment of cancer-associated venous thromboembolism?
This review summarizes the evidence-based NCCN and ASCO guidelines for the comprehensive management of venous thromboembolism in cancer patients.
Answers are grounded in this paper and cite their sources.
Aids clinician application of NCCN/ASCO cancer VTE guidelines; leaves open the need for updated evidence on emerging therapies.
Venous thromboembolism (VTE) is a common complication of cancer and its treatment. The National Comprehensive Cancer Center Network (NCCN) and the American Society of Clinical Oncology (ASCO) have published evidence-based guidelines on the management of VTE in the cancer patient. This paper will review the literature basis and substance of the NCCN and ASCO guidelines. Topics include the prevention, diagnosis, and treatment of deep and superficial vein thrombosis, catheter-associated thrombosis, and pulmonary embolism. Management of recurrent thromboembolism and the use of anticoagulation to improve cancer survival as well as indications for thrombolytic therapy and vena cava filters are also reviewed.
No takes yet. Share an insight, caveat, or question.
Michael B. Streiff (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: